First published on 26 Aug 2015
Vedolizumab for the treatment of adult patients with moderately to severely active Crohn’s disease
Vedolizumab (Entyvio) is recommended. It is a possible option for adults with moderate to severe Crohn’s disease if a tumour necrosis factor (TNF)-alpha inhibitor isn’t suitable or hasn’t worked well enough. People should be able to have vedolizumab until it […]